F.PilegaardH
This article did not independently verify the individuals, starting weights, treatment periods, prescribed formulations, medication doses, adherence, lifestyle interventions, adverse effects, or reported outcomes described in those accounts, and they don't establish an average, typical, or expected result from Zevay's program
Forward-Looking Statements Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, clinical trial study design, status, correspondence, results and data, including related to the completed IMPACT trial, or the ongoing RECLAIM and RESTORE trials, the timing of key milestones for the Companys clinical programs, future plans or expectations for pemvidutide for the treatment of MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy Designations, including potential regulatory timeline and approval benefits, the Companys financial position, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, financial results, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
Unlike human growth hormone, which can induce hyperglycemia and reduce insulin secretion during extended use, AOD-9604 showed no adverse effect on insulin sensitivity even in long-term animal studies confirmed through euglycemic clamp techniques
